Pivotal MVID Trial for Jaguar Health's Crofelemer Advances to Active Treatment Phase
JAGX sits 43% above its 52-week low of $2.53.
Summary
Jaguar Health announced that its pivotal multicenter clinical trial for liquid oral crofelemer in pediatric Microvillus Inclusion Disease (MVID) patients has advanced to an active treatment-only extension phase. This decision, made by an independent data monitoring committee, suggests positive safety and efficacy signals from the initial blinded period. MVID is an ultrarare and lethal pediatric disease with no approved therapies, making crofelemer a critical pipeline asset for Jaguar. This development significantly de-risks the path towards a New Drug Application (NDA), which the company targets for mid-2027. Given Jaguar Health's severe financial distress highlighted in its recent 10-K, this progress on a key drug candidate is highly material and could be transformative for the company's future. Investors should monitor further trial updates and the upcoming data presentation at the ESPGHAN annual meeting in June 2026.
At the time of this announcement, JAGX was trading at $3.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $2.53 to $241.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.